Evidence map›Paper›PMID 40436445›Full record

ArticleBMJ open2025

Protocol for olfactory training in persisting COVID-19-associated loss of smell (SMELL): a monocentric randomised controlled trial conducted in Innsbruck.

Nicolas De Cleene, Frank Jagusch, Joachim Schmutzhard, Timo Gottfried, Marina Peball, Atbin Djamshidian, Philipp Ellmerer, Georg Goebel, Raimund Helbok, Philipp Kindl and 5 more

Registry-linked trialAbstract readClinical Trial Protocol
In one paragraph

Article in BMJ open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05421221 (A Randomized Controlled Trial of the Effectiveness of Olfactory Training on Loss of Smell Related to COVID-19), which is not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05421221 nacompletednot on this map

A Randomized Controlled Trial of the Effectiveness of Olfactory Training on Loss of Smell Related to COVID-19 (SMELL)

TypeinterventionalSponsorMedical University InnsbruckRan2022 to 2024Enrolled70ConditionsCOVID-19, HyposmiaArmsSniffin' sticks Duftquartett
3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. [Herbal treatment options for post-viral symptoms and long COVID].Wiener medizinische Wochenschrift (1946) · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Nicolas De CleeneDepartment of Neurology, Medical University of Innsbruck, Innsbruck, Austria.ORCID http://orcid.org/0009-0000-8177-1381
Frank JaguschDepartment of Neurology, Medical University of Innsbruck, Innsbruck, Austria.
Joachim SchmutzhardDepartment of Otorhinolaryngology, Medical University of Innsbruck, Innsbruck, Austria.
Timo GottfriedDepartment of Otorhinolaryngology, Medical University of Innsbruck, Innsbruck, Austria.
Marina PeballDepartment of Neurology, Medical University of Innsbruck, Innsbruck, Austria.
Atbin DjamshidianDepartment of Neurology, Medical University of Innsbruck, Innsbruck, Austria.
Philipp EllmererDepartment of Neurology, Medical University of Innsbruck, Innsbruck, Austria.
Georg GoebelDepartment of Medical Statistics, Informatics and Health Economics, Medical University of Innsbruck, Innsbruck, Austria.
Raimund HelbokDepartment of Neurology, Medical University of Innsbruck, Innsbruck, Austria.
Philipp KindlDepartment of Neurology, Medical University of Innsbruck, Innsbruck, Austria.
Judith Löffler-RaggDepartment of Internal Medicine II, Medical University of Innsbruck, Innsbruck, Austria.ORCID http://orcid.org/0000-0003-0873-7501
Günter WeissDepartment of Internal Medicine II, Medical University of Innsbruck, Innsbruck, Austria.
Klaus SeppiDepartment of Neurology, Medical University of Innsbruck, Innsbruck, Austria.
Beatrice HeimDepartment of Neurology, Medical University of Innsbruck, Innsbruck, Austria beatrice.heim@i-med.ac.at.
SMELL study-group

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionOlfactory dysfunction (OD) following COVID-19 affected up to 70% of patients, with more than 30% still reporting lingering symptoms a year later. Treatment is essential, as previous research has linked (postviral) OD to depression, impaired quality of life (QoL) and even heightened mortality rates. METHODS AND ANALYSIS: We designed a monocentric, single-blinded randomised controlled trial evaluating the efficacy of olfactory training (OT) in individuals with persisting COVID-19-associated loss of smell. Randomisation will be done in a 1:1 manner. OT will be performed using the Sniffin' Sticks Duft Quartett over a period of 12 weeks, two times per day. The primary endpoint of this study is the change in olfactory score between baseline and after 12 weeks, measured by the combined score of the identification and discrimination subscales of the Sniffin' Sticks testing battery. QoL, overall health, mood, personal well-being and symptom severity will be assessed at baseline and during a follow-up visit, using multiple validated questionnaires and scales. OT is offered to the second cohort during an open-label phase extension. This manuscript highlights and discusses the study protocol. ETHICS AND DISSEMINATION: Ethical approval for the study was obtained from the Ethics Commission of the Medical University of Innsbruck, Austria. Results of this study will be shared through conferences and publications in peer-reviewed journals. TRIAL REGISTRATION NUMBER: NCT05421221.

Indexed as

COVID-19Olfaction DisordersAdultAustriaFemaleHumansMaleMiddle AgedOlfactory TrainingQuality of LifeRandomized Controlled Trials as TopicSARS-CoV-2Single-Blind MethodSmellCOVID-19Quality of LifeRandomized Controlled Trial

Identifiers

PMID40436445
PMCPMC12121588

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.